-
May 13, 2026Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBCSTOCKHOLM – May 13, 2026. Umecrine Cognition today announced new data from the UK-PBC national cohort, to be presented at the EASL Congress 2026 in...
-
April 30, 2026Notice to attend the Annual Shareholders’ Meeting in Umecrine Cognition AB, on May 26, 2026, at 08:30 (am)The shareholders in Umecrine Cognition AB, reg. no. 556698- 3655, are hereby given notice to attend the annual general shareholders’ meeting at...
-
November 19, 2025Umecrine Cognition publishes review highlighting the therapeutic potential of golexanolone in treating neuroinflammatory disordersSTOCKHOLM – November 19, 2025. Umecrine Cognition today announced that a review article on golexanolone, a first-in-class drug candidate targeting...
Latest Annual Report
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.